๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Xinxiang
Clinical trial register · China

Clinical Trials in Xinxiang, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 5484 Shanghai 3827 Guangzhou 3318 Hangzhou 1812 Wuhan 1343
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
The First Affiliated Hospital of Xinxiang Medical College17 MAXVAX Biotechnology Limited Liability Company2 Ganzhou Hemay Pharmaceutical Co., Ltd2 Merck Sharp & Dohme LLC2 Pfizer2
Site location
Beijing5484 Shanghai3827 Guangzhou3318 Hangzhou1812 Wuhan1343
All 613 locations
Target enrolment
to

Trials with a site in Xinxiang

58 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
An Open-label Study of SG1827 Combined With Anti-PD-1/PD-L1 Antibody and Bevacizumab in Patients With Advanced Solid Tumors
NCT07774611Advanced Solid Tumors
Hangzhou Sumgen Biotech Co., Ltd.
Phase 1/2
180
Chongqing, Fuzhou, Guanzhou, Chengde, Haerbin, Xinxiang, Changsha, Changchun
2026-09-22
Not yet open
Efficacy of Low-Dose Laser Acupuncture for Low Back Pain
NCT07461363Chronic Low Back Pain
Mun Fei Yam
Not applicable
80
Xinxiang
2026-09-01
Recruiting
A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
NCT07492680Solid Tumors
Bristol-Myers Squibb
Phase 2
260
Beijing, Chongqing, Guangzhou, Xinxiang, Shanghai
2026-07-27
Not yet open
Xuan Yin Ning Plus Bevacizumab for Malignant Pleural Effusion
NCT07670338Malignant Pleural Effusions (Mpe)
Shanghai Chest Hospital
Not applicable
308
Wuhan, Xinxiang, Weifang, Shanghai
2026-06-01
Recruiting
Mesenchymal Stem Cells in the Treatment of Burn Wounds
NCT07580755Burn Injury, Burn Patients
The First Affiliated Hospital of Xinxiang Medical College
Not applicable
90
Xinxiang
2026-04-27
Recruiting
Efficacy and Safety of Interleukin-6 Receptor Inhibitor Combined With Endovascular Treatment in Patients With Acute Posterior Circulation Large Vessel Occlusion Stroke
NCT07509645Ischemic Stroke
Capital Medical University
Phase 3
348
Suzhou, Anyang, Nanyang, Xinxiang, Zhoukou, Linyi, Zibo, Xianyang
2026-04-22
Recruiting
Tissue Engineered Cartilage to Repairing Articular Cartilage Defects
NCT07094100Cartilage Injury, OA Knee
The First Affiliated Hospital of Xinxiang Medical College
Not applicable
30
Xinxiang
2026-04-20
Recruiting
Screening for Biomarkers of Osteonecrosis of the Femoral Head
NCT07545616Osteonecrosis of the Femoral Head
The First Affiliated Hospital of Xinxiang Medical College
Observational
300
Xinxiang
2026-04-20
Recruiting
Clinical Transformation of Bone Reconstruction With Autologous Bone Marrow Mesenchymal Stem Cells in Vitro to Repair Avascular Necrosis of Femur Head
NCT07101562Avascular Necrosis of Femur Head
The First Affiliated Hospital of Xinxiang Medical College
Not applicable
30
Xinxiang
2026-04-20
Recruiting
Screening for Biomarkers of Osteoarthritis
NCT07544823Osteoarthritis (OA)
The First Affiliated Hospital of Xinxiang Medical College
Observational
300
Xinxiang
2026-04-20
Recruiting
HUMSCs Combined With Col I to Third-Degree Burn Wound
NCT07530003Burn Wounds, Third-Degree Burn Wounds
The First Affiliated Hospital of Xinxiang Medical College
Phase 1/2
108
Xinxiang
2026-04-06
Not yet open
Intracalvariosseous Plus Intravenous Antibiotics for Moderate-to-Severe Bacterial Meningitis
NCT07495150Blood-Brain Barrier, Bacterial Meningitis
yilong Wang
Not applicable
86
Beijing, Kaifeng, Xinxiang, Zhengzhou, Linyi, Tianjin
2026-04-01
Recruiting
Multi-Omics Insights Into Androgenetic Alopecia
NCT07603544Androgenetic Alopecia (AGA)
The First Affiliated Hospital of Xinxiang Medical College
Observational
12
Xinxiang
2026-03-08
Recruiting
Exergames-acceptance and Commitment Therapy(e-ACT) for Breast Cancer Depression and Anxiety: A Randomized Controlled Trial
NCT07721753Breast Cancer Survivors, Depression Anxiety Disorder
Universiti Sains Malaysia
Not applicable
120
Xinxiang
2026-03-01
Recruiting
A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate to Severe Chronic Obstructive Pulmonary Disease
NCT07363694Moderate to Severe Chronic Obstructive Pulmonary Disease
Pfizer
Phase 2/3
1,156
Chizhou, Fuyang, Hefei, Beijing, Guangzhou, Huizhou, Xinxiang, Hohhot
2026-02-11
Recruiting
A Phase II Clinical Study to Evaluate HLX43 in Combination With Serplulimab in Subjects With Advanced Lung Cancer
NCT07253142Non Small Cell Lung Cancer, Small Cell Lung Cancer
Shanghai Henlius Biotech
Phase 2
120
Hefei, Fu'zhou, Guangzhou, Nanning, Cangzhou, Harbin, Xinxiang, Wuha
2026-02-05
Recruiting
Efficacy and Safety of Anricofen Combined With Ciprofol for Deep Sedation in Elderly Patients Undergoing ERCP
NCT07376577Anesthesia, Sedation, ERCP, Ciprofol
The First Affiliated Hospital of Xinxiang Medical College
Not applicable
141
Xinxiang
2026-01-01
Recruiting
Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
NCT07185997Non-Small-Cell Lung Cancer, Metastatic Non-Small-Cell Lung Cancer, Advanced Non-Small-Cell Lung Cancer, EGFR P-Loop and Alpha C-Helix Compressing
ArriVent BioPharma, Inc.
Phase 3
480
Beijing, Xiamen, Foshan, Shantou, Shijiazhuang, Harbin, Luoyang, Xinxiang
2025-12-17
Recruiting
Efficacy and Safety of iGlarLixi Versus Standard of Care in a Real-world Adult China Population With Uncontrolled Type 2 Diabetes on Oral Agents
NCT07307235Type 2 Diabetes
Shanghai Zhongshan Hospital
Phase 4
1,316
Hefei, Huizhou, Shenzhen, Harbin, Xinxiang, Wuhan, Changsha, Hengyang
2025-12-13
Recruiting
Study Evaluating ISM5411 Administered Orally to Subjects With Active Ulcerative Colitis (BETHESDA)
NCT07265570Ulcerative Colitis
InSilico Medicine Hong Kong Limited
Phase 2
80
Beijing, Chongqing, Guangzhou, Huizhou, Nanning, Shijiazhuang, Luoyang, Xinxiang
2025-12-10
Recruiting
A Clinical Study Evaluating the Preliminary Anti-tumor Efficacy and Safety of Hemay181
NCT07446816Advanced Solid Tumors
Ganzhou Hemay Pharmaceutical Co., Ltd
Phase 1
24
Xinxiang
2025-12-03
Recruiting
A Study Comparing TAK-928 With Docetaxel in Adults With Non-Small Cell Lung Cancer
NCT07217301IO-resistant sqNSCLC
Takeda
Phase 3
600
Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Shijiazhuang, Harbin, Xinxiang
2025-11-26
Recruiting
A Study to Assess Safety, Tolerability and Drug Levels of Navlimetostat (BMS-986504) in Participants With Advanced Solid Tumors
NCT07077434Advanced Solid Tumors
Bristol-Myers Squibb
Phase 1
32
Beijing, Fuzhou, Guangzhou, Shenzhen, Harbin, Xinxiang, Jinan, Tianjin
2025-10-15
Active, closed
A Clinical Study of Tulisokibart (MK-7240) to Treat Rheumatoid Arthritis (RA) (MK-7240-014)
NCT07176390Arthritis, Rheumatoid
Merck Sharp & Dohme LLC
Phase 2
182
Beijing, Xiamen, Guangzhou, Xinxiang, Pingxiang, Linfen, รœrรผmqi, Linhai
2025-10-08
Recruiting
VSV-02 Compassionate Use in Advanced Solid Tumors
NCT07260591Advanced Solid Tumor, Melanoma, Breast Cancer, Lung Cancer
The First Affiliated Hospital of Xinxiang Medical College
Phase 1
6
Xinxiang
2025-09-22
Recruiting
A Study of BBT002 in Healthy Volunteers (HVs) and in Patients With Chronic Obstructive Pulmonary Disease (COPD)
NCT07288554Chronic Obstructive Pulmonary Disease (COPD)
Bambusa Therapeutics
Phase 1
68
Hefei, Guangzhou, Jiangmen, Qingyuan, Xinxiang, Yichang, Xuzhou, Nanchang
2025-09-05
Not yet open
RSV in Acute Respiratory Infection Surveillance Among Community-Dwelling Elderly Aged โ‰ฅ50 Years in China
NCT07075029Acute Respiratory Infections (ARIs)
Huashan Hospital
Observational
28,800
Xiamen, Zhuhai, Zunyi, Xinxiang, Yichang, Nanjing, Jiujiang, Shenyang
2025-09-01
Not yet open
Evaluating the Efficacy and Safety of GB08 Injection in Pediatric Patients With Growth Hormone Deficiency
NCT07126288Growth Hormone Deficiency in Children, Growth Hormone Deficiency (GHD), Growth Hormone
Shenzhen Kexing Pharmaceutical Co., Ltd.
Phase 2/3
268
Xiamen, Nanyang, Xinxiang, Wuhan, Suzhou, Nanchang, Pingxiang, Changchun
2025-08-31
Not yet open
AI-Assisted Comprehensive Management for Cancer Patients With Comorbidities (GCOG-CG001)
NCT07136727Oncological Comorbidities (e. g. Hypertension, Diabetes, Malnutrition)
The First Affiliated Hospital of Xinxiang Medical College
Not applicable
5,000
Xinxiang
2025-08-15
Not yet open
Nanocrystalline Megestrol for Managing Chemotherapy-Induced Nausea and Vomiting
NCT07124195Malignant Solid Tumors, Moderate to High Emetogenic Chemotherapy (MEC/HEC) Drugs
The First Affiliated Hospital of Xinxiang Medical College
Phase 3
126
Xinxiang
2025-08-10
Recruiting
Clinical Trial to Evaluate the Efficacy and Safety of EEC for the Diagnosis of Mycobacterium Tuberculosis Infection in People Aged 3 Years and Above
NCT07152639Tuberculosis
Chengdu CoenBiotech Co., Ltd
Phase 3
1,784
Beijing, Hunan, Liuzhou, Xinxiang, Wuhan, Yichang, Chengdu
2025-08-09
Recruiting
Bone Reconstruction With Autologous Bone Marrow Mesenchymal Stem Cells in Vitro to Repair Long Tubular Bone Defects
NCT07066228Defective Composite Restorations, Bone Cysts, Bone Defect, Bone Nonunion
The First Affiliated Hospital of Xinxiang Medical College
Not applicable
30
Xinxiang
2025-08-07
Recruiting
DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
NCT06953089Solid Tumors
DualityBio Inc.
Phase 2
450
Beijing, Dongguan, Henan, Xinxiang, Hubei, Wuhan, Changsha, Xuzhou
2025-07-18
Recruiting
Effects of Ultrasound-guided Recruitment Manoeuvres on Postoperative Pulmonary Complications in OSA Patients Undergoing Total Laparoscopic Hysterectomy
NCT07362680Total Laparoscopic Hysterectomy, Atelectasis, Postoperative
The First Affiliated Hospital of Xinxiang Medical College
Not applicable
90
Xinxiang
2025-05-02
Not yet open
Nanocrystalline Megestrol + Immunochemo As 1st-Line for ES-SCLC Cachexia
NCT06793228SCLC, Extensive Stage
Henan Cancer Hospital
Phase 2
250
Luoyang, Xinxiang, Zhengzhou
2025-01-15
Active, closed
A Study of the Efficacy and Safety of Efgartigimod in Patients With Primary Sjรถgren's Syndrome
NCT06684847Primary Sjogrens Disease
argenx
Phase 3
631
Bengbu, Hefei, Guangzhou, Nanning, Guiyang, Shijiazhuang, Luoyang, Xinxiang
2025-01-15
Recruiting
A Phase โ…  Clinical Study of GEN-725 Tablets in Patients With Advanced Solid Tumors
NCT07229898Advanced Solid Tumors
Henan Genuine Biotech Co., Ltd.
Phase 1
48
Harbin, Jinan, Shanghai, Xinxiang
2025-01-07
Recruiting
Efficacy and Influencing Factors of ALIC-NAc Deep Brain Stimulation in Treatment-Refractory Obsessive-Compulsive Disorder
NCT07031544Obsessive - Compulsive Disorder
Shanghai Mental Health Center
Not applicable
60
Guangzhou, Shijiazhuang, Xinxiang, Nanchang, Taiyuan, Mianyang, Shanghai, Tianjin
2024-12-14
Not yet open
Current Status of Diagnosis and Treatment of Uroepithelial Carcinoma
NCT06663735Uroepithelial Carcinoma
The First Affiliated Hospital of Xinxiang Medical College
Observational
400
Kaifeng, Luoyang, Nanyang, Puyang, Xinxiang, Zhengzhou
2024-10-30
Recruiting
A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.
NCT06629779Metastatic Castration-Resistant Prostate Cancer
Pfizer
Phase 3
900
Wuhu, Beijing, Fuzhou, Guangzhou, Shantou, Guilin, Xinxiang, Zhengzhou
2024-10-22
Not yet open
Current Survey on Chemotherapy-Related Myelosuppression and Clinical Management in Chinese County-level Tumor Patients
NCT06641934Myelosuppression
The First Affiliated Hospital of Xinxiang Medical College
Observational
1,000
Xinxiang
2024-10-20
By invitation
A Phase I/II Clinical Study to Evaluate the Safety and Efficacy of Oral Teslanbaicin in Patients With Radiation Proctitis
NCT06974123Safety
The First Affiliated Hospital of Xinxiang Medical College
Phase 1/2
29
Xinxiang
2024-10-15
Recruiting
Study of LM-299 in Subjects Advanced Malignant Tumors
NCT06650566Malignant Tumors
LaNova Medicines Limited
Phase 1/2
108
Xinxiang, Liaocheng, Zibo, Shanghai
2024-10-09
Recruiting
Induction Chemoimmunotherapy Combined With Chemoradiotherapy in Esophageal Cancer
NCT06421376Esophageal Cancer, Immunotherapy, Induction Therapy, Chemoradiotherapy
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
60
Anyang, Xinxiang, Beijing
2024-05-01
Active, closed
Efficacy and Safety of Concurrent PD-1 Inhibitor and Radiotherapy With Immunonutrition for Esophageal Squamous Cell Carcinoma
NCT06342167Locally Advanced Esophageal Squamous Cell Carcinoma, Sintilimab, Radiotherapy, Concurrent Chemoradiotherapy
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
57
Beijing, Fujian, Handan, Anyang, Xinxiang, Yinchuan, Feixian, Jining
2024-03-14
Active, closed
Innovating Shorter, All- Oral, Precised, Individualized Treatment Regimen for Rifampicin Resistant Tuberculosis๏ผšContezolid, Delamanid and Bedaquiline Cohort
NCT06081361Pulmonary Tuberculosis, Rifampicin-resistant Tuberculosis
Beijing Chest Hospital
Phase 3
186
Beijing, Changsha, Hefei, Jiamusi, Shandong, Xi'an, Xinxiang, Shijiazhuang
2023-12-22
Recruiting
A Study of Efficacy and Safety of Hemay005 Tablets in Patients With Behรงet's Disease
NCT06145893Behรงet's Disease
Ganzhou Hemay Pharmaceutical Co., Ltd
Phase 3
162
Beijing, Xiamen, Guangzhou, Shenzhen, Guilin, Shijiazhuang, Xinxiang, Nanchang
2023-11-13
Recruiting
A Phase I/II Study of FWD1802 in Patients With ER+/HER2- Advanced BC.
NCT06064812Metastatic Breast Cancer, Locally Advanced Breast Cancer, Breast Cancer Stage IV, ER+/HER2- Breast Cancer
Forward Pharmaceuticals Co., Ltd.
Phase 1/2
99
Hefei, Guangzhou, Huizhou, Nanning, Luoyang, Xinxiang, Zhengzhou, Wuhan
2023-09-12
Recruiting
The Safety and Tolerability of LBS-007 in Patients With Relapsed or Resistant Acute Leukaemias
NCT05756322Relapsed or Resistant Acute Leukaemias
Lin BioScience, Inc
Phase 1/2
90
Xinxiang, Jining, Tianjin
2023-07-20
Recruiting
A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)
NCT05319730Esophageal Squamous Cell Carcinoma
Merck Sharp & Dohme LLC
Phase 1/2
230
Hefei, Beijing, Xiamen, Xinxiang, Zhengzhou, Huai'an, Shanghai, Hangzhou
2023-05-16
Active, closed
Immunogenicity and Safety of Recombinant Herpes Zoster Vaccine (CHO Cells) in Healthy Subjects Aged 30 Years and Above
NCT05856084Herpes Zoster
MAXVAX Biotechnology Limited Liability Company
Phase 2
924
Xinxiang
2023-05-07
Recruiting
NKG2D-CAR-NK92 Cells Immunotherapy for Solid Tumors
NCT05528341Relapsed/Refractory Solid Tumors
Henan Medical University
Phase 1
20
Xinxiang
2023-01-26
Active, closed
Prognostic Value of the AMR Measured After PPCI in STEMI Patients
NCT05653765Coronary Heart Disease, ST Elevation Myocardial Infarction
Henan Institute of Cardiovascular Epidemiology
Observational
2,663
Shangqiu, Xinxiang, Yongcheng, Zhengzhou, Shanghai
2022-12-20
Active, closed
Safety and Immunogenicity of Recombinant Herpes Zoster Vaccine (CHO Cells) in Healthy Subjects Aged 18 Years and Above
NCT05636436Herpes Zoster
MAXVAX Biotechnology Limited Liability Company
Phase 1
132
Xinxiang
2022-12-07
Recruiting
Efficacy of Probiotics in Patients With IBD
NCT05652621Ulcerative Colitis, Irritable Bowel Syndrome
The First Affiliated Hospital of Xinxiang Medical College
Not applicable
200
Xinxiang
2022-07-31
Active, closed
A Phase 3 Study of BIBP Diphtheria, Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbed
NCT05091619Whooping Cough, Diphtheria, Tetanus
China National Biotec Group Company Limited
Phase 3
2,898
Anyang, Jiaozuo, Luohe, Xinxiang
2021-10-22
Active, closed
Perioperative Toripalimab (JS001) Combined With Neoadjuvant Chemotherapy in Patients With Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma
NCT04848753Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma
Shanghai Junshi Bioscience Co., Ltd.
Phase 3
663
Bengbu, Hefei, Jiangmen, Shenzhen, Shijiazhuang, Anyang, Xinxiang, Zhengzhou
2021-05-12
Active, closed
Phase 3 Study of MRTX849 (Adagrasib) vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation
NCT04685135Metastatic Non Small Cell Lung Cancer, Advanced Non Small Cell Lung Cancer
Mirati Therapeutics Inc.
Phase 3
453
Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Liuzhou, Harbin, Xinxiang
2021-02-23
Rows per page Showing 1–58 of 58
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 24 September 2026. https://priyalifescience.com/clinical-trials-china/city/xinxiang

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 58 of those studies with a site in Xinxiang.

How many clinical trials are recruiting in Xinxiang?

36 of the 58 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 11 have not yet opened recruitment, 10 are active but closed to new participants, and 1 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Xinxiang), 58 studies
PhaseStudiesRecruitingShare
Not applicable13922.4%
Phase 312620.7%
Phase 29515.5%
Observational7312.1%
Phase 17612.1%
Phase 1/27512.1%
Phase 2/3213.4%
Phase 4111.7%

Most active sponsors

Lead sponsors with the most studies (Xinxiang)
Lead sponsorStudiesRecruiting
The First Affiliated Hospital of Xinxiang Medical College1712
Bristol-Myers Squibb22
Cancer Institute and Hospital, Chinese Academy of Medical Sciences21
Ganzhou Hemay Pharmaceutical Co., Ltd22
MAXVAX Biotechnology Limited Liability Company20
Merck Sharp & Dohme LLC21
Pfizer22
argenx10
ArriVent BioPharma, Inc.11
Bambusa Therapeutics11
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.